University of Auckland research could help solve the mystery of the migraine
The University of Auckland has published new findings on the discovery of a potential new drug target for the treatment of migraines. Migraines, a common but debilitating neurological disorder, have puzzled scientists for centuries. Current strategies for developing new migraine treatments are based on the knowledge that people who suffer from migraines have elevated levels of a pain-causing hormone called CGPR (calcitonin gene-related peptide).
Therefore the medication that has been developed in recent years, drugs called ‘gepants’, has worked by blocking CGRP activity at the CGRP receptor.
However, new research from the University of Auckland shows that another receptor, called AMY1, also plays a crucial role in CGPR activity during migraine attacks. Associate Professor Hayes from the university says "...we have discovered that CGPR activates a second target on the surface of pain-sensing nerve cells, called AMY1, which gepants are not designed to block. This may be the key to treating migraines and opens the door for the design of new drugs that block this second target."
You can read more about this story on the University of Auckland website. Contact Study Options if you would like to find out more about study or research in New Zealand.